GlobeNewswire

New Axonify Study Reveals Microlearning Key to Enabling an Agile Frontline Workforce

Dela

First-of-its-Kind 2018 Microlearning Global Benchmark Report Highlights Progressive Organisations Reimagining Training

WATERLOO, Ontario, July 25, 2018 (GLOBE NEWSWIRE) -- Highlighting the influence microlearning has in enabling an agile workforce, Axonify, the most trusted corporate microlearning platform, today launched the first-of-its-kind 2018 Microlearning Global Benchmark Report. The comprehensive analysis of microlearning covers general trends, adoption, demographics and industry applications based on usage data from 360,000 employees at 78 organisations using Axonify.

The report reveals how continuous microlearning takes learning measurement beyond traditional metrics like test scores and completion rates by providing stakeholders across the business with a real-time view of what employees know or don't know so that they can proactively respond to address gaps. According to the report, microlearning offers universal appeal among frontline-driven organisations and drives high levels of employee engagement directly impacting business results. Data shows that on average, employees utilising microlearning know 85 percent of the information they are required to know to perform on-the-job compared to 73% when they started.

Also, the report highlighted that three quarters of employees participate in microlearning training sessions at a rate of two to three times weekly, and it is heavily used in fast-paced, agile industries with a large number of frontline employees, including Retail (27 percent), Manufacturing and Logistics (25 percent) and Finance and Insurance (22 percent).

"Microlearning resonates with frontline workers because it's a habit-forming style of learning that fits seamlessly into their agile work environment-the first thing they do at the start of a shift or when they have downtime," said Carol Leaman, CEO of Axonify. "Traditionally, getting employees to participate in training has been tough, but that isn't the case with microlearning. It automatically adapts learning so each session is based on what an employee knows or doesn't know including game mechanics for increased engagement."

Anatomy of a Microlearning Session

Employees participating in microlearning training every month, do so two to three times per week which translates into more than 100 training sessions per year. Averaging six minutes per day, microlearning sessions typically start with critical messages from senior management, followed by personalised training, casual game play and rewards. Employees exposed to microlearning incorporating game play and game mechanics participate at a rate of 52 percent more, experiencing average knowledge lift of 27 percent.

"Microlearning is now becoming mainstream," said Josh Bersin, Global Industry Analyst. "This important research proves the value of this new paradigm and gives us all a clear roadmap for success."

Based on Axonify's research, organisations most often use microlearning to train their employees on:

  1. Product Knowledge
  2. Safety
  3. Sales
  4. HR/Corporate Culture
  5. Customer Service

"Fosway's research shows that almost two-thirds of organisations are planning to adopt microlearning this year, so it is clearly a growth area. But as with all buzzwords, there is a lot of hype and not enough context around the use and advantages of microlearning," said David Perring, Director of Research, Fosway Group. "This new report sheds light on some of its real-world application across a broad range of industries."

Retailers Take Advantage of Microlearning to Train Employees About Promotions

Retail, the largest cluster of organisations in Axonify's study includes frontline store associates across a variety of sectors including brand retailers, big box, grocery, and specialty retail. Across the industries covered in Axonify's report, retail employees have the highest Current Knowledge and Confidence at 84 percent, and their participation rate is high at 85 percent.

Aside from utilizing microlearning to advance product knowledge and safety measures, retailers are providing microlearning to train employees on promotions at a rate more than two times the industry average. Retailers are also embracing daily microlearning reinforcement as a critical preventative measure to keep shrink rates at bay using asset protection and loss prevention training.

Manufacturing and Logistics Mitigate Safety Risks with Microlearning

Manufacturers are increasingly turning to microlearning as a better way to mitigate high safety risks. In fact, safety training in Manufacturing and Logistics occurs at a rate of three times more than Finance and Insurance and almost two times more than retail. Safety training is the second most popular type of training offered, next to product knowledge, by manufacturing organisations as they work to achieve a company culture of safety.

Additionally, according to the study, microlearning helped lift manufacturing and logistics employees' product knowledge up to 91.4 percent. Also, based on their microlearning sessions, these professionals average a Current Knowledge and Confidence level of 83 percent with a 72 percent participation rate.

Methodology

The insights presented in the 2018 Microlearning Global Benchmark Report were generated by anonymously analysing a sample of 360,000 employees across 78 organisations, and nearly four million microlearning sessions that occurred between January 1, 2017 and December 31, 2017. This included a variety of industries and organisations ranging from mid-sized to large Fortune 100 companies-that are capturing millions of learning data points as employees engage in their daily training using the Axonify Microlearning Platform. 

For more information, visit https://axonify.com/benchmark-report/.

About Axonify

Axonify is the only microlearning platform trusted by global business leaders to drive performance. With a proven approach that's based in brain science, and uses adaptive microlearning and gamification to make employee learning effective and engaging, our platform ingrains knowledge deep enough to change employee behaviour at work. With more than 130 customers in 95 countries around the world, including Walmart, Bloomingdale's, and John Hancock, Axonify makes learning personal to the individual, and impactful for the business. Founded in 2011, Axonify is headquartered in Waterloo, ON Canada. For more information, please visit www.axonify.com.

Media Contact: 
Jennifer Mirabile
Young & Associates
724-772-2038
jenniferlm@yapr.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Axonify via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum